Journal of SAFOMS

Register      Login

VOLUME 5 , ISSUE 1 ( January-June, 2017 ) > List of Articles

REVIEW ARTICLE

Management of Postmenopausal Vaginal Atrophy: Review of Literature

Meena Dayal, Preeti Yadav

Citation Information :

DOI: 10.5005/jp-journals-10032-1105

Published Online: 00-00-0000

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim

As there is dilemma for treatment of postmenopausal vaginal atrophy, effort has been made to review the literature for the same.

Background

About half of all postmenopausal women will experience symptoms related to urogenital atrophy. Vaginal atrophy becomes clinically apparent 4 to 5 years after menopause, and subjective complaints as well as objective changes are present in 25 to 50% of all postmenopausal women.

Review results

Measures could be taken for not only treatment but also prevention of atrophy before symptoms become troublesome, but establishment of this prevention principle globally would require a formal cost-effective analysis and further research.

Conclusion

Treatment with local estrogen is simple, safe, and can transform a woman’s quality of life.

Clinical significance

Women experiencing sexual and urinary symptoms as a consequence of vaginal atrophy should be diagnosed and treated without delay in order to avoid a cascade of events which do not resolve spontaneously.

How to cite this article

Yadav P, Dayal M. Management of Postmenopausal Vaginal Atrophy: Review of Literature. J South Asian Feder Menopause Soc 2017;5(1):51-57.


  1. Assessment of the variation in menopausal symptoms with age, education and working/non-working status in north-Indian sub population using menopause rating scale (MRS). Maturitas 2007 Jul;57(3):306-314.
  2. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010 Jan-Feb;17(1):194-203.
  3. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA 1983 Apr;249(16):2195-2198.
  4. Impact of menopause on collagen subtypes in the arcus tendineous fasciae pelvis. Am J Obstet Gynecol 2004 Mar;190(3):620-627.
  5. Collagen metabolism in the uterosacral ligaments and vaginal skin of women with uterine prolapse. BJOG 2006 Jan;113(1):39-46.
  6. Age-related pelvic floor modifications and prolapse risk factors in postmeno-pausal women. Menopause 2010 Jan-Feb;17(1):204-212.
  7. Diagnosis and treatment of atrophic vaginitis. Am Fam Phys 2000 May;61(10):3090-3096.
  8. Estrogen deprivation and vaginal function in postmenopausal women. JAMA 1982 Jul;248(4):445-448.
  9. Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy. Can J Microbiol 2005 Sep;51(9):777-781.
  10. Prevalence and determinants of vaginal flora alterations in postmenopausal women. J Infect Dis 2003 Oct;188(7):1054-1058.
  11. Prevalence and persistence of human papillomavirus in postmenopausal age women. Cancer Detect Prev 2003;27(6):472-480.
  12. Changes in urethral cytology following estrogen administration. Gynecol Obstet Invest 1990;29(3):211-213.
  13. Histomorphometric study of the lower urogenital tract in pre- and post-menopausal women. Cytometry 1990;11(6):700-707.
  14. Vaginal pH as a marker for bacterial pathogens and menopausal status. Am J Obstet Gynecol 1997 Jun;176(6):1270-1275.
  15. The menopause and HRT. Urogenital effects of hormone therapy. Best Pract Res Clin Endocrinol Metab 2003 Mar;17(1):91-104.
  16. The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence. BJOG 2002 Mar;109(3):339-344.
  17. Development and validation of a physical examination scale to assess vaginal atrophy and inflammation. Climacteric 1999 Sep;2(3):197-204.
  18. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for industry. Estrogen and estrogen/progestin drug products to treat vasomotor symp-toms and vulvar and vaginal atrophy symptoms – recom-mendations for clinical evaluation (Draft Guidance). Rockville (MD): US Department of Health and Human Services, Food and Drug Administration; 1997. Available from: http://http :// www.fda.gov /cder/guidance /5412dft.pdf.
  19. Biological and psychosocial pathophysiology of female sexual dysfunction during the menopause transition. J Sex Med 2005 Sep;2(Suppl 3):133-145.
  20. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998 Oct;92(4 Pt 2):722-727.
  21. Urogenital atrophy. Climacteric 2009 Aug;12(4):279-285.
  22. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996 Apr;23(3):259-263.
  23. Low-dose vaginal estrogens or vaginal moistuizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010 Jun;26(6):404-412.
  24. Effects of red clover isoflavones (Promensil) versus placebo on uterine endometrium, vaginal maturation index and the uterine artery in healthy post-menopausal women. J Br Menopause Soc 2004 Jun;10:17.
  25. Menopausal years: the wise woman way – alternative approaches for women. Woodstock (NY): Ash Tree; 1992.
  26. The effects of postmenopausal Vitamin D treatment on vaginal atrophy. Maturitas 2004 Dec;49(4):334-337.
  27. Oral pilocarpine to treat vaginal xerosis associated with chemotherapy-induced amenorrhoea in premenopausal women. J Clin Oncol 2004 Jul;22(14 Suppl):8099.
  28. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006 Nov-Dec;13(6):917-925.
  29. Complementary therapies for managing the menopause: has there been any progress? Climacteric 2010 Jun;13(3):201-202.
  30. Meno-pausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol 2005 May;105(5 Pt 1):1063-1073.
  31. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health (Larchmt) 2010 Mar;19(3):425-432.
  32. Local oestrogen therapy for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006 Oct;4:CD001500.
  33. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric 2010 Jun;13(3):228-237.
  34. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005 Mar;8(1):883-892.
  35. Efficacy and safety of low dose regimens of conjugated estrogen cream administered vaginally. Menopause 2009 Jul-Aug;16(4):719-727.
  36. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009 Apr;12(2):91-105.
  37. IMS Updated Recommendations on postmenopausal hormone therapy. Climacteric 2007 Jun;10(3):181-194.
  38. Estrogen and progestogen use in postmenopausal women; 2010 statement of the North American Menopause Society. Menopause 2010 Mar;17(2):242-255.
  39. Differential expression of oestrogen receptor isoforms and androgen receptor in the normal vulva and vagina compared with vulval lichen sclerosus and chronic vaginitis. Br J Dermatol 2008 Feb;158(2):319-328.
  40. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 2010 Mar;7(3):1284-1290.
  41. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009 Sep-Oct;16(5):907-922.
  42. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009 Sep-Oct;16(5):923-931.
  43. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007 May-Jun;14(3 Pt 1):357-369.
  44. Safety of vaginal oestrogen in postmenopausal women. Obstet Gynaecol 2005 Oct;7(4):241-244.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.